Churg-Strauss Syndrome
23
3
3
13
Key Insights
Highlights
Success Rate
81% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
13.0%
3 terminated out of 23 trials
81.3%
-5.3% vs benchmark
22%
5 trials in Phase 3/4
46%
6 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (23)
Hydroxychloroquine in ANCA Vasculitis Evaluation
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NUCALA® Special Drug Use Investigation (EGPA, Long-term)
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
VCRC Tissue Repository
Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan
Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921
Eosinophilic Granulomatosis With Polyangiitis Cohort
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
VCRC Patient Contact Registry Patient-Reported Data Validation Study
A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome
PRO Development for ANCA Associated Vasculitis
Vasculitis Illness Perception (VIP) Study
Educational Needs of Patients With Systemic Vasculitis
Reproductive Health in Men and Women With Vasculitis
Rituxan in Churg Strauss Syndrome With Renal Involvement
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides